Docking Peptides for Targeted Antibody Drug Conjugates

USPTO published patent application US20260109780A1 disclosing novel docking peptides enabling controlled attachment of drug moieties and tumor-targeting moieties in antibody-based drug conjugates. The invention aims to enhance targeted delivery of drug payloads to tumor microenvironments with a controlled drug-to-antibody ratio (DAR). CPC classifications indicate pharmaceutical and peptide chemistry applications, with therapeutic use in cancer treatment (A61P 35/00).

For parties in the pharmaceutical or biotechnology sector working on antibody-drug conjugates or targeted drug delivery systems, this patent application establishes prior art in docking peptide technology and controlled DAR conjugation methods. Companies developing similar targeted therapeutic platforms should review the claimed peptide structures and conjugation approaches to assess potential freedom-to-operate considerations.